Life Time Fitness, Inc. (LTM) Tops Q1 EPS by 1c; Boosts FY12 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LTM Hot Sheet
Price: $46.27 -2.01%
Financial Fact:
Center operations: 193.29M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Center operations: 193.29M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Life Time Fitness, Inc. (NYSE: LTM) reported Q1 EPS of $0.62, $0.01 better than the analyst estimate of $0.61. Revenue for the quarter came in at $268.4 million versus the consensus estimate of $271.1 million.
Memberships grew 8.2% to 704,467 at March 31, 2012, from 650,784 at March 31, 2011. Memberships up 3.8% excluding acquisitions.
Life Time Fitness, Inc. sees FY2012 EPS of $2.65-$2.73, versus prior guidance of $2.60-$2.72 and the consensus of $2.75. Life Time Fitness, Inc. sees FY2012 revenue of $1.11-$1.1.35 billion, versus the consensus of $1.13 billion.
For earnings history and earnings-related data on Life Time Fitness, Inc. (LTM) click here.
Memberships grew 8.2% to 704,467 at March 31, 2012, from 650,784 at March 31, 2011. Memberships up 3.8% excluding acquisitions.
Life Time Fitness, Inc. sees FY2012 EPS of $2.65-$2.73, versus prior guidance of $2.60-$2.72 and the consensus of $2.75. Life Time Fitness, Inc. sees FY2012 revenue of $1.11-$1.1.35 billion, versus the consensus of $1.13 billion.
For earnings history and earnings-related data on Life Time Fitness, Inc. (LTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
